Table 1. Details of the participants and general measures adopted during the COVID 19 pandemic.

Question	Answer	N (%) (Total n = 148)	Not answered
General section
Practice setting	Academic institute: Government	36 (24.3)
	Academic institute: Private	76 (51.4)
	Non academic: Private	34 (23.0)
	Non academic: government hospital	2 (1.4)
Specialty	Gynaecologic Oncologist	74 (50.0)
	Surgical Oncologist	26 (17.6)
	Medical Oncologist	21 (14.2)
	Radiation Oncologist	12 (8.1)
	Gynaecologist	15(10.1)
Gynaecological cancer patients seen per month (before the onset of COVID-19)	<50	84 (56.8)
	51–100	30 (20.3)
	101–250	14 (9.5)
	>250	20 (13.5)
Gynaecological cancer surgeries per month (before the onset of COVID-19)	<10	41 (27.7)		28 (18.9)
	11–20	38 (25.7)
	21–30	18 (12.2)
	>30	23 (15.5)
States with high volume of confirmed COVID–19 cases	>3,500	75 (50.7)
	≤3,500	73 (49.3)
Decrease in practice after COVID 19 Pandemic	No	6 (4.1)
	Yes	142 (95.9)
Decreased practice in percentage	No surgery	3 (2.0)		1 (0.7)
	<10% of usual volume	39 (26.4)
	About 1/4th of usual volume	58 (39.2)
	About 1/2 of usual volume	30 (20.3)
	About 3/4th of usual volume	14 (9.5)
	No change	3 (2.0)
MDTB in COVID 19 pandemic	Not conducted	72 (48.6)
	Conducted	76 (51.4)
Mode of MDTB if Yes	Virtual tumour board	54 (36.5)		60 (40.5)
	Tumour board with <5 participants	23 (15.5)
	Tumour board with 6–10 participants	9 (6.1)
	As before	2 (1.4)
RT PCR before cancer treatment	Yes	60 (40.5)
	Only selected high risk patients as per Institutional policy	64 (43.2)
	COVID 19 testing not mandatory	24 (16.2)
Additional precautions in view of COVID 19 pandemic	No	13 (8.8)
	Yes	135 (91.2)
Various additional precaution	No precaution	1 (0.7)		25 (16.9)
	N95 mask and visor	65 (44)
	Full PPE	51 (34.4)
	Full PPE and reduce personnel in OT	6 (4)
Smoke evacuator during surgery	No	80 (54)		5 (3.4)
	Yes	63 (42.6)